PPT-Dolutegravir-Lamivudine (

Dovato Last Updated November 28 2022 Prepared by Brian R Wood MD David H Spach MD DolutegravirLamivudine Photograph courtesy of ViiV INSTI NRTI 50 mg 300 mg DolutegravirLamivudine. GENERIC ARVs. Tim Horn. Treatment Action Group. tim.horn@treatmentactiongroup.org. Federal AIDS Policy Partnership Meeting. December 2014. Patents and Exclusivity 101 . Myriad Policies. Patents issued >1996 have term of 20 years. David Spach, MD. Clinical Director, Northwest AETC. Professor of Medicine, Division of Infectious Diseases. University of Washington. Last Updated: October 21, 2013. 2013 . Asilomar. Update. New Occupational . New Treatments for HIV. C. Ryan Tomlin, . Pharm.D. ., BCPS, AAHIVP. Mercy Health Saint Mary’s. Grand Rapids, Michigan. Outline. Newly Released Antiretroviral Medications. Isentress. HD. ® (. raltegravir. New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) . HIV positive people in low- and middle-income countries including South Africa can be treated for around R900 (US $75 a year) . HIV Drug Resistance (HIVDR) and Antimicrobial Resistance (AMR): Science and Action. IAS 2017 . Paris . 24. th. July 2017. Modelling the cost and cost-effectiveness of responses to . HIV drug resistance. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. SWORD-1 . and SWORD-. 2. Dolutegravir plus Rilpivirine as Maintenance Dual Therapy. SWORD-1 and SWORD-2: Design. Source: . Llibre. JM, et al. Lancet. 2018;39:839-49.. Background. : . Identical, randomized, multinational, open-label, industry-sponsored, parallel-group, . –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . SPRING-2 Study. Dolutegravir. versus Raltegravir. SPRING-2: Design. Source: . Raffi. F, et al. Lancet. 2013;381:735-43.. Dolutegravir. : 50 mg QD. Fixed-dose NRTI backbone*. (n = 411). Raltegravir. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food. Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. R. egimens . m. ay Need . O. ptimization for Youth Failing ART. V Kouamou. , J Manasa, D Katzenstein, A McGregor, CE Ndhlovu, A T Makadzange, PESU Study Team. C. onflict . of . Interest . D. eclaration.